MicroRNA-137 regulates a glucocorticoid receptor-dependent signalling network: Implications for the etiology of schizophrenia

Journal of Psychiatry and Neuroscience

Volumn 39, Issue 5, 2014, Pages 312-320

  Vallès, Astrid ^a,b   Martens, Gerard J M ^b   De Weerd, Peter ^a,c   Poelmans, Geert ^b,c,d   Aschrafi, Armaz ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; DEUBIQUITINASE; DUAL SPECIFICITY PHOSPHATASE; EARLY GROWTH RESPONSE FACTOR 2; GLUCOCORTICOID RECEPTOR; INSULIN RECEPTOR SUBSTRATE 2; KRUPPEL LIKE FACTOR 4; MEDIATOR COMPLEX; MICRORNA; MICRORNA 137; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; OLIGONUCLEOTIDE; PROSTAGLANDIN SYNTHASE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; UNCLASSIFIED DRUG; MIRN137 MICRORNA, HUMAN; MIRN137 MICRORNA, MOUSE; MIRN137 MICRORNA, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; ENVIRONMENTAL ENRICHMENT; GENE SILENCING; GENETIC ASSOCIATION; MICROARRAY ANALYSIS; MOLECULAR GENETICS; MOUSE; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; RNA EXTRACTION; SCHIZOPHRENIA; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL HOUSING; BRAIN CORTEX; ENVIRONMENT; HUMAN; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALS; CEREBRAL CORTEX; ENVIRONMENT; HOUSING, ANIMAL; HUMANS; MICRORNAS; NEURONAL PLASTICITY; NEURONS; RECEPTORS, GLUCOCORTICOID; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84906808322     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.130269     Document Type: Article

References (72)

1. Boshes RA, Manschreck TC, Konigsberg W. Genetics of the schizophrenias: a model accounting for their persistence and myriad phenotypes. Harv Rev Psychiatry 2012;20:119-29.
2. Rodriguez-Murillo L, Gogos JA, Karayiorgou M. The genetic architecture of schizophrenia: new mutations and emerging paradigms. Annu Rev Med 2012;63:63-80.
3. Mulle JG. Schizophrenia genetics: progress, at last. Curr Opin Genet Dev 2012;22:238-44.
4. Perkins DO, Jeffries CD, Jarskog LF, et al. MicroRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007;8:R27.
5. Ambros V. The functions of animal microRNAs. Nature 2004; 431:350-5.
6. Petersen CP, Bordeleau ME, Pelletier J, et al. Short RNAs repress translation after initiation in mammalian cells. Mol Cell 2006; 21:533-42.
7. Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466:835-40.
8. Olde Loohuis NF, Kos A, Martens GJ, et al. MicroRNA networks direct neuronal development and plasticity. Cell Mol Life Sci 2012;69:89-102.
9. McNeill E, Van Vactor D. MicroRNAs shape the neuronal landscape. Neuron 2012;75:363-79.
10. Schouten M, Aschrafi A, Bielefeld P, et al. MicroRNAs and the regulation of neuronal plasticity under stress conditions. Neuroscience 2013;241:188-205.
11. Impey S, Davare M, Lesiak A, et al. An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling. Mol Cell Neurosci 2010;43:146-56.
12. Luikart BW, Perederiy JV, Westbrook GL. Dentate gyrus neurogenesis, integration and microRNAs. Behav Brain Res 2012;227:348-55.
13. Paschou M, Paraskevopoulou MD, Vlachos IS, et al. MiRNA regulons associated with synaptic function. PLoS ONE 2012;7:e46189.
14. Gardiner E, Beveridge NJ, Wu JQ, et al. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry 2012;17:827-40.
15. Xu B, Hsu PK, Stark KL, et al. Derepression of a neuronal inhibitor due to miRNA dysregulation in a schizophrenia-related microdeletion. Cell 2013;152:262-75.
16. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011;43:969-76.
17. Green MJ, Cairns MJ, Wu J, et al. Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Mol Psychiatry 2013;18:774-80.
18. Whalley HC, Papmeyer M, Romaniuk L, et al. Impact of a microRNA MIR137 susceptibility variant on brain function in people at high genetic risk of schizophrenia or bipolar disorder. Neuropsychopharmacology 2012;37:2720-9.
19. van Erp TG, Guella I, Vawter MP, et al. Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation. Biol Psychiatry 2014;75:398-405.
20. Lett TA, Chakavarty MM, Felsky D, et al. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Mol Psychiatry 2013;18:443-50.
21. Smrt RD, Szulwach KE, Pfeiffer RL, et al. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells 2010;28:1060-70.
22. Willemsen MH, Valles A, Kirkels LA, et al. Chromosome 1p21.3 microdeletions comprising DPYD and MIR137 are associated with intellectual disability. J Med Genet 2011;48:810-8.
23. Szulwach KE, Li X, Smrt RD, et al. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol 2010; 189:127-41.
24. Seshadri S, Zeledon M, Sawa A. Synapse-specific contributions in the cortical pathology of schizophrenia. Neurobiol Dis 2013;53:26-35.
25. Yin DM, Chen YJ, Sathyamurthy A, et al. Synaptic dysfunction in schizophrenia. Adv Exp Med Biol 2012;970:493-516.
26. Maragkakis M, Alexiou P, Papadopoulos GL, et al. Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics 2009;10:295.
27. Maragkakis M, Reczko M, Simossis VA, et al. DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res 2009;37:W273-6.
28. Feldman DE, Brecht M. Map plasticity in somatosensory cortex. Science 2005;310:810-5.
29. Polley DB, Kvasnak E, Frostig RD. Naturalistic experience transforms sensory maps in the adult cortex of caged animals. Nature 2004;429:67-71.
30. Vallès A, Boender AJ, Gijsbers S, et al. Genomewide analysis of rat barrel cortex reveals time-and layer-specific mRNA expression changes related to experience-dependent plasticity. J Neurosci 2011;31:6140-58.
31. Dweep H, Sticht C, Pandey P, et al. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011;44:839-47.
32. Benjamini Y, Hochberg Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Educ Behav Stat 2000;25:60-83.
33. Pike N. Using false discovery rates for multiple comparisons in ecology and evolution. Methods in Ecology and Evolution 2011;2:278-82.
34. Poelmans G, Pauls DL, Buitelaar JK, et al. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry 2011;168:365-77.
35. Poelmans G, Franke B, Pauls DL, et al. AKAPs integrate genetic findings for autism spectrum disorders. Transl Psychiatr 2013; 3:e270.
36. Wright C, Turner JA, Calhoun VD, et al. Potential Impact of miR-137 and Its Targets in Schizophrenia. Front Genet 2013;4:58.
37. Kim AH, Parker EK, Williamson V, et al. Experimental validation of candidate schizophrenia gene ZNF804A as target for hsamiR-137. Schizophr Res 2012;141:60-4.
38. Kwon E, Wang W, Tsai LH. Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol Psychiatry 2013;18:11-2.
39. Fletcher PC, Frith CD. Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat Rev Neurosci 2009;10:48-58.
40. Javitt DC. Sensory processing in schizophrenia: neither simple nor intact. Schizophr Bull 2009;35:1059-64.
41. Adcock RA, Dale C, Fisher M, et al. When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia. Schizophr Bull 2009;35:1132-41.
42. McOmish CE, Burrows E, Howard M, et al. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Mol Psychiatry 2008;13:661-72.
43. Rajasethupathy P, Fiumara F, Sheridan R, et al. Characterization of small RNAs in aplysia reveals a role for miR-124 in constraining synaptic plasticity through CREB. Neuron 2009;63:803-17.
44. Nudelman AS, DiRocco DP, Lambert TJ, et al. Neuronal activity rapidly induces transcription of the CREB-regulated microRNA-132, in vivo. Hippocampus 2010;20:492-8.
45. Cohen JE, Lee PR, Chen S, et al. MicroRNA regulation of homeostatic synaptic plasticity. Proc Natl Acad Sci U S A 2011;108:11650-5.
46. Schratt GM, Tuebing F, Nigh EA, et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006;439:283-9.
47. Siegel G, Obernosterer G, Fiore R, et al. A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat Cell Biol 2009;11:705-16.
48. Fiore R, Khudayberdiev S, Christensen M, et al. Mef2-mediated transcription of the miR379-410 cluster regulates activity-dependent dendritogenesis by fine-tuning Pumilio2 protein levels. EMBO J 2009;28:697-710.
49. Fitzsimons CP, van Hooijdonk LW, Schouten M, et al. Knockdown of the glucocorticoid receptor alters functional integration of newborn neurons in the adult hippocampus and impairs fear-motivated behavior. Mol Psychiatry 2013;18:993-1005.
50. Jafari M, Seese RR, Babayan AH, et al. Glucocorticoid receptors are localized to dendritic spines and influence local actin signaling. Mol Neurobiol 2012;46:304-15.
51. Polman JA, Welten JE, Bosch DS, et al. A genome-wide signature of glucocorticoid receptor binding in neuronal PC12 cells. BMC Neurosci 2012;13:118.
52. Liston C, Cichon JM, Jeanneteau F, et al. Circadian glucocorticoid oscillations promote learning-dependent synapse formation and maintenance. Nat Neurosci 2013;16:698-705.
53. Webster MJ, Knable MB, O'Grady J, et al. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 2002;7:985-94.
54. Van Craenenbroeck K, De Bosscher K, Vanden Berghe W, et al. Role of glucocorticoids in dopamine-related neuropsychiatric disorders. Mol Cell Endocrinol 2005;245:10-22.
55. Vreugdenhil E, Verissimo CS, Mariman R, et al. MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology 2009; 150:2220-8.
56. Geekiyanage H, Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer's disease. J Neurosci 2011;31:14820-30.
57. Cross-Disorder Group of the Psychiatric Genomics Consortium; Genetic Risk Outcome of Psychosis (GROUP) Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013;381:1371-9.
58. Escribano L, Simon AM, Perez-Mediavilla A, et al. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 2009;379:406-10.
59. Gil-Bea FJ, Aisa B, Solomon A, et al. HPA axis dysregulation associated to apolipoprotein E4 genotype in Alzheimer's disease. J Alzheimers Dis 2010;22:829-38.
60. Silverman JL, Yang M, Turner SM, et al. Low stress reactivity and neuroendocrine factors in the BTBR T+tf/J mouse model of autism. Neuroscience 2010;171:1197-208.
61. Braun S, Kottwitz D, Nuber UA. Pharmacological interference with the glucocorticoid system influences symptoms and lifespan in a mouse model of Rett syndrome. Hum Mol Genet 2012;21:1673-80.
62. Borlikova GG, Trejo M, Mably AJ, et al. Alzheimer brain-derived amyloid beta-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging 2013;34:1315-27.
63. Chung L, Bey AL, Jiang YH. Synaptic plasticity in mouse models of autism spectrum disorders. Korean J Physiol Pharmacol 2012; 16:369-78.
64. Ebert DH, Greenberg ME. Activity-dependent neuronal signaling and autism spectrum disorder. Nature 2013;493:327-37.
65. Levenga J, Willemsen R. Perturbation of dendritic protrusions in intellectual disability. Prog Brain Res 2012;197:153-68.
66. Beveridge NJ, Santarelli DM, Wang X, et al. Maturation of the human dorsolateral prefrontal cortex coincides with a dynamic shift in microRNA expression. Schizophr Bull 2013 [Epub ahead of print].
67. Guella I, Sequeira A, Rollins B, et al. Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. J Psychiatr Res 2013;47:1215-21.
68. Yao ZH, Zhang JJ, Xie XF. Enriched environment prevents cognitive impairment and tau hyperphosphorylation after chronic cerebral hypoperfusion. Curr Neurovasc Res 2012;9:176-84.
69. Beauquis J, Pavia P, Pomilio C, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease. Exp Neurol 2013;239:28-37.
70. Restivo L, Ferrari F, Passino E, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci U S A 2005;102: 11557-62.
71. Schneider T, Turczak J, Przewlocki R. Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism. Neuropsychopharmacology 2006;31:36-46.
72. Lacaria M, Spencer C, Gu W, et al. Enriched rearing improves behavioral responses of an animal model for CNV-based autistic-like traits. Hum Mol Genet 2012;21:3083-96.